PF-Atlas › Clinical Trials › NCT00957242

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

warfarin · Phase 3

Registry ID

NCT00957242

Phase

Phase 3

Status

Terminated

Drug / intervention

warfarin

Sponsor

Duke University

Start

2009-10

Enrollment

145

Locations

About this trial

This study will test the effectiveness of warfarin in patients with IPF. Approximately 256 patients will be randomized 1:1 to either warfarin or placebo. Patients will return at week 1 for a safety review and every 16 weeks for 48 weeks. The primary endpoint in the study is the time to either death, non-bleeding/non-elective hospitalization, or a drop of greater than 10% in forced vital capacity (FVC) from baseline.

View NCT00957242 on ClinicalTrials.gov →

Explore related

All warfarin trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT00957242 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.